HIV-associated Hodgkin lymphoma

Current Opinion in HIV and AIDS

Volumn 4, Issue 1, 2009, Pages 3-10

  Carbone, Antonino ^a   Gloghini, Annunziata ^a   Serraino, Diego ^b   Spina, Michele ^b  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

Author keywords

Epstein Barr virus; HIV associated Hodgkin lymphoma; HIV AIDS; Hodgkin lymphoma

Indexed keywords

ANTINEOPLASTIC AGENT; ANTIRETROVIRUS AGENT; BLEOMYCIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DIDANOSINE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; LATENT MEMBRANE PROTEIN 1; NAVELBINE; PREDNISONE; PROCARBAZINE; VINBLASTINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE MARROW TOXICITY; CANCER ADJUVANT THERAPY; CANCER EPIDEMIOLOGY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER RISK; CANCER SURVIVAL; CD4 CD8 RATIO; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; DISEASE ASSOCIATION; DRUG MEGADOSE; EPSTEIN BARR VIRUS; EVENT FREE SURVIVAL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HISTOPATHOLOGY; HODGKIN DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE DEPLETION; MULTIPLE CYCLE TREATMENT; NEUROTOXICITY; OPPORTUNISTIC INFECTION; OVERALL SURVIVAL; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; VIRUS PATHOGENESIS;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; B-LYMPHOCYTES; BLEOMYCIN; CLINICAL TRIALS, PHASE II AS TOPIC; DACARBAZINE; DOXORUBICIN; HODGKIN DISEASE; HUMANS; LYMPHOMA, AIDS-RELATED; RISK FACTORS; T-LYMPHOCYTES; VINBLASTINE; VIRAL MATRIX PROTEINS;

EID: 67849135601     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e32831a722b     Document Type: Review

References (50)

1. Engels EA, Pfeiffer RM, Goedert JJ, et al. Trends in cancer risk among people with AIDS in the United States 1980-2002. AIDS 2006; 20:1645-1654.
2. Biggar RJ, Jaffe ES, Goedert JJ, et al. Hodgkin lymphoma and immunodeficiency in persons with HIV/AIDS. Blood 2006; 108:3786-3791.
3. Jaffe ES, Harris NL, Stein H, et al., editors. World Health Organization classification of tumours: pathology and genetics, tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2001.
4. Swerdlow SH, Campo E, Jaffe ES, et al., editors. World Health Organization classification of tumours: pathology and genetics, tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2008.
5. Grogg KL, Miller RF, Dogan A. HIV infection and lymphoma. J Clin Pathol 2007; 60:1365-1372.
6. Tirelli U, Errante D, Dolcetti R, et al. Hodgkin's disease and human immunodeficiency virus infection: clinicopathologic and virologic features of 114 patients from the Italian Cooperative Group on AIDS and Tumors. J Clin Oncol 1995; 13:1758-1767.
7. Curado MP, Edwards B, Shin HR, et al., editors. Cancer incidence in five continents. Vol.IX IARC Scientific Publications No. 160. Lyon: IARC; 2007.
8. Hjalgrim H, Askling J, Pukkala E, et al. Incidence of Hodgkin's disease in Nordic countries. Lancet 2001; 358:297-298. (Pubitemid 32738971)
9. Cockfield SM. Identifying the patient at risk for posttransplant lymphoproliferative disorder. Transplant Infect Dis 2001; 3:70-78. (Pubitemid 32452921)
10. Carbone A, Gloghini A, Larocca LM, et al. Human immunodeficiency virus-associated Hodgkin's disease derives from postgerminal center B cells. Blood 1999; 93:2319-2326. (Pubitemid 29153635)
11. Biggar RJ, Horm J, Goedert JJ, et al. Cancer in a group at risk of acquired immunodeficiency syndrome (AIDS) through 1984. Am J Epidemiol 1987; 126:578-586.
12. Hessol NA, Katz MH, Liu JY, et al. Increased incidence of Hodgkin disease in homosexual men with HIV infection. Ann Intern Med 1992; 117:309-311.
13. Serraino D, Carbone A, Franceschi S, et al. Increased frequency of lymphocyte depletion and mixed cellularity subtypes of Hodgkin disease in HIV-infected patients. Italian Cooperative Group on AIDS and Tumours. Eur J Cancer 1993; 29A:1948-1950.
14. Serraino D, Pezzotti P, Dorrucci M, et al. Cancer incidence in a cohort of human immunodeficiency virus seroconveters. HIV Italian Seroconverters Study Group. Cancer 1997; 79:1004-1008. (Pubitemid 27089884)
15. Franceschi S, Dal Maso L, Arniani D, et al. Risk of cancer other than Kaposi sarcoma and non-Hodgkin's lymphoma in persons with AIDS in Italy. Cancer and AIDS Registry Linkage Study. Br J Cancer 1998; 78:966-970.
16. International Collaboration on HIV and Cancer. Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults. J Natl Cancer Inst 2000; 92:1823-1830.
17. Grulich AE, Li Y, McDonald A, et al. Rates of non-AIDS-defining cancers in people with HIV infection before and after AIDS diagnosis. AIDS 2002; 16:1155-1161. (Pubitemid 34533854)
18. Dal Maso L, Franceschi S, Polesel J, et al. Risk of cancer in persons with AIDS in Italy, 1985-1998. Br J Cancer 2003; 89:94-100.
19. Herida M, Mary-Krause M, Kaphan R, et al. Incidence of non AIDS-defining cancers before and during the highly active antiretroviral therapy era in a cohort of human immunodeficiency virus-infected patients. J Clin Oncol 2003; 21:3447-3453. (Pubitemid 46594077)
20. Clifford GM, Polesel J, Rickenbach M, et al. Cancer risk in the Swiss HIV cohort study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy. J Natl Cancer Inst 2005; 97:425-432. (Pubitemid 40528605)
21. Serraino D, Piselli P, Busnach G, et al. Risk of cancer following immunosuppression in organ transplant recipients and in HIV-positive individuals in southern Europe. Eur J Cancer 2007; 43:2117-2123. (Pubitemid 47381577)
22. Engels EA, Biggar RJ, Hall HI, et al. Cancer risk in people infected with human immunodeficiency virus in the United States. Int J Cancer 2008; 123:187-194. (Pubitemid 351705208)
23. Said JW. Immunodeficiency-related Hodgkin lymphoma and its mimics. Adv Anat Pathol 2007; 14:189-194.
24. Rezk SA, Weiss LM. Epstein-Barr virus-associated lymphoproliferative disorders. Hum Pathol 2007; 38:1293-1304. This review article highlights the importance of EBV infection in the pathogenesis of Hodgkin lymphoma and NHL.
25. Carbone A, Gloghini A, Dotti G. EBV-associated lymphoproliferative disorders: classification and treatment. Oncologist 2008; 13:577-585. (Pubitemid 351872874)
26. Klein U, Dalla-Favera R. Germinal centres: role in B-cell physiology and malignancy. Nat Rev Immunol 2008; 8:22-33. This review focuses on the role of germinal centers in B-cell physiology. The authors discuss its implication for the pathogenesis of B-cell lymphomas.
27. Vockerodt M, Morgan S, Kuo M, et al. The Epstein-Barr virus oncoprotein, latent membrane protein-1, reprograms germinal centre B cells towards a Hodgkin's Reed-Sternberg-like phenotype. J Pathol 2008; 216:83-92. The study reports on the possible contribution of EBV-encoded latent membrane protein 1 (LMP1) to the global loss of B-cell identity, given that gene expression profiles revealed that LMP1 induced in germinal center B cells transcriptional changes of Hodgkin cell lines.
28. Gloghini A, Carbone A. Why would the incidence of HIV-associated Hodgkin lymphoma increase in the setting of improved immunity? Int J Cancer 2007; 120:2753-2754. The study deals with the reasons why the incidence of HIV-associated Hodgkin lymphoma has increased since HAART was introduced. This study adds to our understanding of the role of the background on Hodgkin lymphoma development.
29. Alvaro T, Lejeune M, García JF, et al. Tumor-infiltrated immune response correlates with alterations in the apoptotic and cell cycle pathways in Hodgkin and Reed-Sternberg cells. Clin Cancer Res 2008; 14:685-691. The study shows that a lower level of cytotoxic cells correlates with an increase of antiapoptotic mechanism in Reed-Sternberg cells. (Pubitemid 351231148)
30. Carbone A, Cabras A, Gloghini A. HIV-associated Hodgkin's lymphoma. Antiapoptotic pathways and mechanisms for immune escape by tumor cells in the setting of improved immunity. Int J Biol Markers 2007; 22:161-163. (Pubitemid 47062222)
31. Tirelli U, Vaccher E, Serraino D, et al. Comparison of presenting clinical and laboratory findings of patients with persistent generalized lymphadenopathy (PGL) syndrome and malignant lymphoma (ML). Haematologica 1987; 72:563-565.
32. Andrieu JM, Roithmann S, Tourani JM, et al. Hodgkin's disease during HIV-1 infection: the French registry experience. Ann Oncol 1993; 4:635-641. (Pubitemid 23291808)
33. Rubio R. Hodgkin's disease associated with human immunodeficiency virus infection. A clinical study of 46 cases. Cancer 1994; 73:2400-2407.
34. Garcìa-Noblejas A, Nieto S, Liberal R, et al. Intracerebral Hodgkin's lymphoma in a patient with human immunodeficiency virus. Haematologica 2007; 92:e72-e73.
35. Vaccher E, Spina M, Talamini R, et al. Improvement of systemic human immunodeficiency virus-related NHL in the era of HAART. Clin Infect Dis 2003; 37:1556-1564.
36. Chimienti E, Spina M, Gastaldi R, et al. Clinical characteristics and outcome of 290 patients (pts) with Hodgkin's disease and HIV infection (HD-HIV) in pre and HAART (highly active antiretroviral therapy) era [abstract 168]. Ann Oncol 2008; 19:iv136.
37. Berenguer J, Miralles P, Ribera JM, et al. Characteristics and outcome of AIDS-related Hodgkin lymphoma before and after the introduction of highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2008; 47:422-428. The authors report the differences in clinical presentation and outcome in 104 patients with Hodgkin disease and HIV infection treated or not with HAART showing the significative impact of antiretroviral therapy on the outcome of lymphoma.
38. Errante D, Tirelli U, Gastaldi R, et al. Combined antineoplastic and antiretroviral therapy for patients with Hodgkin's disease and human immunodeficiency virus infection. A prospective study of 17 patients. Cancer 1994; 73:437-444.
39. Errante D, Gabarre J, Ridolfo AL, et al. Hodgkin's disease in 35 patients with HIV infection: an experience with epirubicin, bleomycin, vinblastine and prednisone chemotherapy in combination with antiretroviral therapy and primary use of G-CSF. Ann Oncol 1999; 10:189-195. (Pubitemid 29113179)
40. Levine AM, Li P, Cheung T, et al. Chemotherapy consisting of doxorubicin, bleomycin, vinblastine and dacarbazine with granulocyte-colony-stimulating factor CSF in HIV infected patients with newly diagnosed Hodgkin's disease: a prospective, multi-institutional AIDS Clinical Trials Group study (ACTG 149). J Acquir Immune Defic Syndr 2000; 24:444-450. (Pubitemid 30828761)
41. Spina M, Gabarre J, Rossi G, et al. Stanford V and concomitant HAART in 59 patients with Hodgkin's disease and HIV infection. Blood 2002; 100:1984-1988. (Pubitemid 35001227)
42. Hartmann P, Rehwald U, Salzberger B, et al. BEACOPP therapeutic regimen for patients with Hodgkin's disease and HIV infection. Ann Oncol 2003; 14:1562-1569. (Pubitemid 37304614)
43. Xicoy B, Ribera JM, Miralles P, et al. Results of treatment with doxorubicin, bleomycin, vinblastine and dacarbazine and highly active antiretroviral therapy in advanced stage human immunodeficiency virus-related Hodgkin's lymphoma. Haematologica 2007; 92:191-198. The authors report a large series of patients treated with the standard ABVD regimen. They demonstrated for the first time the feasibility and high activity of the combination of ABVD and HAART in patients with Hodgkin disease and HIV. (Pubitemid 46860198)
44. Xicoy B, Ribera JM, Romeu J, et al. Response to highly active antiretroviral therapy as the only therapy in an HIV-infected patient with interfollicular Hodgkin's lymphoma. Haematologica 2007; 92:191-198. This is an interesting report showing the possibility of a complete remission using HAART as front-line treatment for a selected case of Hodgkin lymphoma and HIV.
45. Spina M, Rossi G, Antinori A, et al. VEBEP regimen and highly active antiretroviral therapy (HAART) in patients (pts) with HD and HIV infection (HD-HIV) [abstract 227]. Ann Oncol 2008; 19:iv152.
46. Gabarre J, Marcelin AG, Azar N, et al. High-dose therapy plus autologous hematopoietic stem cell transplantation for human immunodeficiency (HIV)- related lymphoma: results and impact on HIV disease. Haematologica 2004; 89:1100-1108. (Pubitemid 39295481)
47. Re A, Cattaneo C, Michieli M, et al. High-dose therapy and autologous peripheral blood stem cell transplantation as salvage treatment for HIVassociated lymphoma in patients receiving highly active antiretroviral therapy. J Clin Oncol 2003; 21:4423-4427. (Pubitemid 46621820)
48. Krishnan A, Molina A, Zaia J, et al. Durable remission with autologous stem cell transplantation for high-risk HIV-associated lymphomas. Blood 2005; 105:874-878. (Pubitemid 40070778)
49. Serrano D, Carrion R, Balsalobre P, et al. HIV-associated lymphoma successfully treated with peripheral blood stem cell transplantation. Exp Hematol 2005; 33:487-494. (Pubitemid 40387632)
50. Spitzer TR, Ambinder RF, Lee JY, et al. Dose-reduced busulfan, cyclophosphamide, and autologous stem cell transplantation for human immunodeficiency virus-associated lymphoma: AIDS Malignancy Consortium Study 020. Biol Blood Marrow Transplant 2008; 14:59-66. The authors report a series of patients treated with reduced dose of busulfan and cyclophosphamide as conditioning regimen for patients with HIV-related lymphomas demonstrating the possibility to have an alternative regimen to the classical BEAM.